International Stem Cell Corp. (ISCO)

[capital gain]

NT 10Q filed.


http://knobias.10kwizard.com/files.php?alld=ON&sym=isco

they came in at $1,515,000 for the quarter, that is a very respectable 555 % incease over first quarter 2010 were revenue were $279,000

Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in the subject report or portion thereof? x Yes ¨ No

If so, attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons why a reasonable estimate of the results cannot be made.

As previously announced, International Stem Cell Corporation (the “Company”) introduced its initial Lifeline Skin Care (“LSC”) products in late 2010. During its first quarter of 2011, the Company recognized revenues from the sale of those LSC products. There were no sales of LSC products in the first quarter of the previous year. Principally, as a result of those LSC product sales, revenues for the first fiscal quarter increased to approximately $1,515,000 (from approximately $273,000 in the first quarter of 2010). As a result of increases in cost of sales, research and development and general and administrative expenses, total development expenses increased to approximately $3,828,000 (from approximately $2,440,000 in the first quarter of 2010).

Lets see what tomorrow brings. Looks great to mee.

GLTA.

A.H